| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Quest Diagnostics announced Tuesday it will acquire the US laboratory testing business of Oxford Immunotec Global for $170 million in cash. As part of the definitive agreement reached by the companies, the acquisition will include the T-Spot.TB tuberculosis testing service and the Accutix tick-borne disease testing service provided by Oxford Immunotec laboratories in Norwood, Massachusetts and in Memphis, Tennessee. Oxford Immunotec is headquartered in Abingdon, UK.
More than half of Americans tested by Quest Diagnostics in 2017 misused prescription drugs, a statistic that has remained relatively flat and suggests that medication adherence is more difficult as the opioid epidemic swells. The misuse rate — meaning tests reveal additional drugs (non-prescribed or illicit), different medications than prescribed, or no prescription or illicit drugs — was 52% in 2017 and 2016, and has remained relatively stagnant since 2013, according to Quest Diagnostics' analysis of 3.9 million clinical drug monitoring tests administered between 2011 and 2017.
Hooper Holmes, Inc. d/b/a Provant Health , the largest publicly traded, pure-play health and well-being provider in the U.S., today announced that it has entered into an asset purchase agreement with Summit Health, Inc., a subsidiary of Quest Diagnostics (“Quest”), the world’s leading provider of diagnostic testing, information, and services. Under the asset purchase agreement, Quest will acquire substantially all of Provant Health’s assets and will continue the Company’s service offerings as it has in the past. Throughout the transaction process, Provant Health will continue to serve its customers, remaining focused on meeting customer and partner obligations in the busy fourth quarter season.
Blockchain technology is currently known for keeping cryptocurrency transactions secure. With adaptations, it may soon be used to keep personal health information more safe and secure, as its name suggests, than ever before. The current model for storing data is by keeping said data stored in one place. For example, a Microsoft Word document is saved to a desktop. While access to that document may be made through the server, even remotely, it is still saved in a single, centralized location. Blockchain is, arguably, the exact opposite.Over the summer, UnitedHealthcare, Humana, Optum, Quest Diagnostics and MultiPlan launched a pilot program using blockchain technology to assist payers in tackling mandated provider directories. The program utilizes the technology to reduce costs associated with insurers updating demographic data from providers.
It’s been years since the tobacco industry promised to stop luring young people to smoke cigarettes. Philip Morris International says it is “designing a smoke-free future.” British American Tobacco, likewise, claims to be “transforming tobacco” into a safer product. But while the Food and Drug Administration weighs plans to cut nicotine in cigarettes, making them less addictive, Big Tobacco has been making the most of the time it still has using social networks to promote its brands around the world.
Tom Romeo, general manager of healthcare IT and Quanum Solutions at Quest Diagnostics, said hospitals and health systems must identify the cause of insurance claim denials to ensure proper and timely payment. "Identify the source of denials through reports and discussions with staff, and then prioritize fixing the problem," he told Becker's Hospital Review. "Train staff about these issues and review top denials regularly in meetings with physicians. It's critical to recognize the contribution of every employee in the denial-management process."
As more women put off starting families and U.S. fertility rates drop, helping women assess how much time, and how many eggs, they have left to conceive is a growing business. The market for ovulation tests, fertility monitors and other mail-in home tests to help women up their odds of bearing fruit is exploding. Several startups are selling kits that allow women to test their fertility at home with a simple finger prick. Modern Fertility allows women to send a blood sample drawn by pricking a finger or having blood drawn at a lab and tested at Quest Diagnostics. The at-home test is mailed back and then screened.
A group of newborn infants with genetic disorders that went undetected in standard testing will receive genomic sequencing in a clinical study of its safety and feasibility. The study is led by a team at Tufts University Medical Center in Boston, and conducted at another 5 sites in the U.S., supported by a 5-year, $8 million grant from National Center for Advancing Translational Science, or NCATS, part of National Institutes of Health. The trial is recruiting 400 newborns with potential genetic disorders that were not detected in standard screenings. The infants will receive whole genomic sequencing, as well as targeted genomic tests for 1,722 inherited disorders known to affect newborns, developed with Quest Diagnostics, a nationwide network of medical labs.
Earlier this year, five prominent healthcare organizations—Humana, MultiPlan, Quest Diagnostics, and UnitedHealth Group’s Optum and UnitedHealthcare—announced they would be launching a blockchain-based pilot program with the aim to improve healthcare data quality and reduce administrative costs.
An emerging bacterial threat, mycoplasma genitalium, that can be passed through sex is making some headlines across the pond as the British Association of Sexual Health and HIV recently drafted guidance aimed at better detecting and treating it. Commercial labs such as Quest Diagnostics offer a test for this STD.
The threat of Lyme disease has spread to all 50 states. Quest Diagnostics analyzed 6 million blood samples and found the tick-borne disease is now in 100 percent of the country. The most cases were in Pennsylvania, but the disease is also becoming more common in places like Florida and California.
The proportion of workplace drug tests detecting the use of marijuana, cocaine and methamphetamine is up sharply, from 3.2 percent in 2012 to 4.2 percent, according to Quest Diagnostics. With the Trump economy producing more jobs than applicants, some companies are simply dropping pot from their routine pre-employment drug screening. “Employers are saying, ‘We have a thin labor pool,’” employment lawyer James Reidy tells the Associated Press. “So are we going to test and exclude a whole group of people?”
Lyme disease is now in all 50 states and the number of cases is rising, according to a report from clinical laboratory Quest Diagnostics. The tick-borne illness, historically found mostly in the Northeast, is now growing rapidly in California and Florida, where it was not usually found in the past, according to a report from clinical laboratory Quest Diagnostics.
The New York Times reported yesterday that a new-to-the-United-States tick species has been identified in seven states in recent months, after an infestation was first discovered last summer in New Jersey. The tick is native to Asia, where it is known to carry a dangerous virus that kills 15% of the people it bites. But it has spread in recent years—to Australia, New Zealand, several Pacific islands, and now to America.
This really bites and sucks. The tick population continues to grow, Lyme Disease continues to spread, and now according to a recently released analysis from Quest Diagnostics Lyme Disease can be found in all 50 states plus Washington, D.C.
If you thought you were safe from Lyme disease because you don’t live in New England, where the tick-borne illness first appeared, think again. Now, 100 percent of the country — all 50 states plus the District — has residents who have tested positive for Lyme, a bacterial infection that can cause a wide variety of symptoms, including joint aches, fatigue, facial palsy and neck stiffness.
Every state in the nation reported residents who tested positive for Lyme disease, according to the most recent Quest Diagnostics study released last week. No longer is the tick-borne disease simply an issue for people living in New England, where it first appeared and is still prevalent.
A new report has found that the tick-borne illness Lyme disease has been detected in all 50 states, and cases continue to rise. The report from Quest Diagnostics is based on more than six million blood tests taken over the last seven years, CBS New York reports. The New Jersey-based clinical laboratory says cases of Lyme disease have exploded in areas like California and Florida, where it was not commonly seen in the past. The company believe ticks are finding it easier to survive in new regions and spreading diseases to unsuspecting residents.
While Lyme disease once was thought to be as reliably of New England as lockjaw and lobster rolls, the tick-borne ailment that hits both young children and older adults especially hard is now officially everywhere, at least according to a new study from lab giant Quest Diagnostics.
Participants in the BFOR study sign up for genetic testing at no cost by logging on to the website (www.BFORStudy.com) and answering a series of questions to determine eligibility. Educational videos explain the specifics of the test, the purpose of genetic testing and its importance. In all, the registration process takes no more than an hour. The site also allows patients to schedule genetic-testing appointments at the offices of Quest Diagnostics, which has several locations in each of the four cities. They can opt to have results sent to a personal physician or a health-care provider on the BFOR study team.
A new study by Quest Diagnostics has ranked Georgia third in the nation for the most increases in Lyme disease between 2015 and 2017.
here's been a sharp spike in Lyme disease cases in the United States, and the tick-borne illness has now spread to all 50 states, a new report shows. "Lyme disease is a bigger risk to more people in the United States than ever before," said Dr. Harvey Kaufman, senior medical director for Quest Diagnostics, which conducted the study.
Blockchain is here to stay. Here is what we need to do to make it better.
Last month’s Alzheimer’s Association International Conference (AAIC) 2018 heralded many announcements, including the mixed reception around Phase II trials results from Biogen’s Alzheimer’s drug BAN2401. Like many treatments in AD, it addressed build up of amyloid plaques in the brain. However, many drug failures in that area, as well as Pfizer’s exodus from Alzheimer’s and Parkinson’s research early this year, has led to investors and scientists to reevaluate the plaque theory. Edward I. Ginns, MD, PhD, medical director, neurology, for Quest Diagnostics, said, “When we see patients at the point of clinical identification, the brain is pretty much out of resources. It’s unlikely that neurons that are dead or non-functional will be treated at that late stage.” To that end, Quest Diagnostics wanted to identify patients with cognition problems earlier. They developed CogniSense, a cognition test that is available as an app for the iPad and given in the primary care doctor’s office.